The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease

The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease

AimsGiven the compelling evidence on the effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the conventional heart failure population, SGLT2i deserve exploration in systemic right ventricular (sRV) failure. The initial experience with dapagliflozin in sRV failure patients is desc...

Full description

Bibliographic Details
Main Authors: Ralph M. L. Neijenhuis, Marieke Nederend, Monique R. M. Jongbloed, Philippine Kiès, Joris I. Rotmans, Hubert W. Vliegen, J. Wouter Jukema, Anastasia D. Egorova
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
congenital heart disease
adult congenital heart disease (ACHD)
heart failure
systemic right ventricle
sodium glucose co-transport-2 (SGLT2) inhibitors
transposition of the great arteries (TGA)
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1093201/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1093201/full

Similar Items